In vitro and ex vivo assays to demonstrate your drugs’ efficacy</p>
<p>

In vitro and ex vivo assays for drug targeting obesity/type 2 diabetes and NASH/MASH

To limit the use of animals and support our customers combatting obesity/type 2 diabetes and NASH/MASH.

Physiogenex offers its experience/expertise and a panel of in vitro and ex vivo services.

Optimize and expedite your preclinical drug development programs with our validated systems of adipocytes (human and rodent), muscle (rodent), hepatocyte steatosis model (HepaRG, monolayer), 3D NASH model (human hepatocytes, Kupffer cells and Stellate cells in spheroids culture).

Our validated in vitro and ex vivo assays

Lipolysis / glucose uptake on isolated adipocytes

Human adipocytes (lipolysis)

Human adipocytes (glucose uptake):

Mouse adipocytes (glucose uptake):

Glucose uptake on isolated muscle

Mouse muscle:

Simple hepatocytes or 3D spheroid models

Screening/efficacy tests on Hepa-RG®:

Liver spheroids for MASH/fibrosis:

Preclinical CRO Services for obesity, insulin resistance and diabetes

In vivo drug efficacy experiments

Muscles/adipocytes ex vivo glucose uptake
Muscles/adipocytes ex vivo FFA oxydation
Adipocytes ex vivo lipolysis

All our ex vivo assays

In vivo drug efficacy experiments

Glucose homeostasis

Glucose and insulin tolerance test
Hyperinsulinemic euglycemic/hyperglycemic clamps with 3H-glucose (hepatic glucose production, turnover, glycolysis, etc.) and 14C-2-deoxyglucose (glucose uptake)
In vivo individual tissue glucose uptake

Lipid metabolism

Lipid tolerance test
Lipogenesis in vivo with 3H2O or 14C-acetate

in vivo studies

In vivo services

Body weight food/water intake, organs collection, weight and fixation (fat pads, liver, etc.), blood collection and tissue dissection
Cardiometabolic parameters (echocardiography)
Indirect calorimetry (energy expenditure), Echo MRI (body composition)

in vivo studies